-
公开(公告)号：US07183390B2
公开(公告)日：2007-02-27
申请号：US09992524
申请日：2001-11-13
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24
摘要： The invention provides humanized immunoglobulins that bind to and neutralize γ-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.
摘要翻译： 本发明提供结合并中和γ-干扰素的人源化免疫球蛋白。 抗体可用于治疗免疫系统疾病，特别是自身免疫性疾病。
-
公开(公告)号：US06329511B1
公开(公告)日：2001-12-11
申请号：US09450520
申请日：1999-11-29
IPC分类号： C07K1600
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24
摘要： The invention provides humanized immunoglobulins that bind to and neutralize &ggr;-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.
摘要翻译： 本发明提供结合并中和γ-干扰素的人源化免疫球蛋白。 抗体可用于治疗免疫系统疾病，特别是自身免疫性疾病。
-
公开(公告)号：US20110250213A1
公开(公告)日：2011-10-13
申请号：US13082352
申请日：2011-04-07
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2317/76
摘要： The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.
摘要翻译： 本发明提供了特异性结合CD122的单克隆抗体，CD122是IL-2和IL-15受体的一个组分。 通过抑制这些细胞因子与其受体的结合，单克隆抗体具有对IL-2和IL-15介导的功能的显着抑制的能力。 除了其它应用之外，单克隆抗体可用于抑制不期望的免疫应答或癌症的治疗。
-
公开(公告)号：US20080063646A1
公开(公告)日：2008-03-13
申请号：US10581468
申请日：2004-11-10
IPC分类号： A61K39/395 , A61P29/00 , C07K16/00 , C07K16/24
CPC分类号： C07K16/24 , C07K2317/24 , C07K2317/76 , Y02E60/324
摘要： The present invention is directed to high affinity anti-human IP-10 antibodies or antigen-binding fragments of these antibodies, including chimeric, humanized or fully human antibodies. The present invention is also directed to a method of reducing the severity of at least one symptom of an inflammatory bowel disease in a subject in need thereof comprising administering to said subject an effective amount of an antagonist of IP-10, including the antibodies or antibody fragments of the present invention.
摘要翻译： 本发明涉及高亲和力抗人IP-10抗体或这些抗体的抗原结合片段，包括嵌合，人源化或完全人抗体。 本发明还涉及降低有需要的受试者中至少一种炎症性肠病症状的严重性的方法，其包括对所述受试者施用有效量的IP-10拮抗剂，包括抗体或抗体 本发明的片段。
-
公开(公告)号：US09028830B2
公开(公告)日：2015-05-12
申请号：US13082352
申请日：2011-04-07
IPC分类号： A61K39/395 , C07K16/00 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2317/76
摘要： The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.
摘要翻译： 本发明提供了特异性结合CD122的单克隆抗体，CD122是IL-2和IL-15受体的一个组分。 通过抑制这些细胞因子与其受体的结合，单克隆抗体具有对IL-2和IL-15介导的功能的显着抑制的能力。 除了其它应用之外，单克隆抗体可用于抑制不期望的免疫应答或癌症的治疗。
-
公开(公告)号：US07935793B2
公开(公告)日：2011-05-03
申请号：US10581468
申请日：2004-11-10
IPC分类号： C07K16/24 , A61K39/395
CPC分类号： C07K16/24 , C07K2317/24 , C07K2317/76 , Y02E60/324
摘要： The present invention is directed to high affinity anti-human IP-10 antibodies or antigen-binding fragments of these antibodies, including chimeric, humanized or fully human antibodies. The present invention is also directed to a method of reducing the severity of at least one symptom of an inflammatory bowel disease in a subject in need thereof comprising administering to said subject an effective amount of an antagonist of IP-10, including the antibodies or antibody fragments of the present invention.
摘要翻译： 本发明涉及高亲和力抗人IP-10抗体或这些抗体的抗原结合片段，包括嵌合，人源化或完全人抗体。 本发明还涉及降低有需要的受试者中至少一种炎症性肠病症状的严重性的方法，其包括对所述受试者施用有效量的IP-10拮抗剂，包括抗体或抗体 本发明的片段。
-
7.发明授权公开(公告)号：US07223393B2
公开(公告)日：2007-05-29
申请号：US10774076
申请日：2004-02-06
IPC分类号： A61K39/395
CPC分类号： G01N33/574 , A61K47/6855 , A61K2039/505 , C07K16/22 , C07K2317/73 , G01N2333/485
摘要： The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention also provides a method of treating cancer or psoriasis in a subject in need of such a treatment by administering such antibodies to said subject in a pharmaceutically effective amount.
摘要翻译： 本发明涉及抗AR抗体，优选具有本文公开的氨基酸序列的人源化单克隆抗体。 本发明包括含有这种抗体的药物组合物。 本发明包括抑制癌细胞生长的方法，其包括向受试者施用此类抗体。 本发明还提供了通过以药学上有效量向所述受试者施用这种抗体来治疗需要这种治疗的受试者中的癌症或牛皮癣的方法。
-
公开(公告)号：US20080107595A1
公开(公告)日：2008-05-08
申请号：US11581944
申请日：2006-10-16
IPC分类号： A61K39/395 , C07K16/18 , A61K51/00 , A61P43/00 , C12N5/06
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii), two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
摘要翻译： 本发明涉及抗CCR5抗体，其包含（i）两条轻链，每条轻链包含命名为pVK：HuPRO140-VK（ATCC保藏号PTA-4097）的质粒的表达产物，和（ii）两个重的 每个重链包含命名为pVg1：HuPRO140HG2-VH（ATCC保藏号PTA-4098）的质粒或称为pVg1：HuPRO140（mutB + D + I）-VH的质粒（ATCC保藏号PTA- 4099）或其与人细胞表面上的CCR5结合的片段。
-
公开(公告)号：US20050032114A1
公开(公告)日：2005-02-10
申请号：US10687118
申请日：2003-10-15
申请人： Paul Hinton , Naoya Tsurushita , J. Tso , Maximiliano Vasquez
发明人： Paul Hinton , Naoya Tsurushita , J. Tso , Maximiliano Vasquez
CPC分类号： C07K16/082 , C07K16/00 , C07K16/249 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
-
公开(公告)号：US08591894B2
公开(公告)日：2013-11-26
申请号：US12976282
申请日：2010-12-22
申请人： David M Holtzman , Ronald DeMattos , Kelly R. Bales , Steven M. Paul , Naoya Tsurushita , Maximiliano Vasquez
发明人： David M Holtzman , Ronald DeMattos , Kelly R. Bales , Steven M. Paul , Naoya Tsurushita , Maximiliano Vasquez
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide Aβ.
摘要翻译： 描述了以预防和治疗形成淀粉样斑块为特征的病症的治疗方法。 该方法使用人源化抗体，其从人类生物流体中螯合可溶性Aβ肽，或者优选特异性结合淀粉样蛋白β肽Abeta位置13-28中包含的表位。
-
-
-
-
-
-
-
-
-
搜索结果
60 条记录 (耗时 0.034 秒)
